Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Eisai to present new cancer research at ASCO 2011

Eisai to present new cancer research at ASCO 2011

20th May 2011

Eisai has revealed plans to present 19 new cancer research abstracts at the American Society of Clinical Oncology (ASCO) annual meeting for 2011.

Taking place next month, the event will see Eisai share data on new treatments for oncology-related conditions including acute myeloid leukaemia (AML), thyroid cancer, metastatic breast cancer and ovarian cancer.

The presentations will include results from a phase III trial of the injection-based compound decitabine, which has been trialled as a treatment for older patients with newly-diagnosed AML.

Meanwhile, further phase III analysis will be conducted to assess the impact of palonosetron, ondansetron, dolasetron and granisetron in controlling chemotherapy-induced nausea and vomiting.

The company said: "These studies highlight Eisai's current product portfolio and oncology pipeline, reinforcing the company's commitment to address the diverse needs of patients and their families affected by cancer."

Last month, Eisai introduced Halaven to the UK market, an innovative new treatment for breast cancer.ADNFCR-8000103-ID-800550948-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.